US Bancorp’s Supernus Pharmaceuticals SUPN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$9.54K Sell
205
-1,635
-89% -$78.5K ﹤0.01% 3458
2026
Q1
$95.1K Buy
1,840
+63
+4% +$3.21K ﹤0.01% 2413
2025
Q4
$88.3K Sell
1,777
-618
-26% -$30K ﹤0.01% 2444
2025
Q3
$114K Sell
2,395
-3,170
-57% -$128K ﹤0.01% 2289
2025
Q2
$175K Sell
5,565
-596
-10% -$19.1K ﹤0.01% 2105
2025
Q1
$202K Buy
6,161
+104
+2% +$3.69K ﹤0.01% 1992
2024
Q4
$219K Buy
6,057
+18
+0.3% +$634 ﹤0.01% 1985
2024
Q3
$188K Buy
6,039
+76
+1% +$2.37K ﹤0.01% 2062
2024
Q2
$160K Sell
5,963
-88
-1% -$2.55K ﹤0.01% 2112
2024
Q1
$206K Buy
6,051
+453
+8% +$13.5K ﹤0.01% 1992
2023
Q4
$162K Sell
5,598
-68
-1% -$1.8K ﹤0.01% 2113
2023
Q3
$156K Sell
5,666
-385
-6% -$11.7K ﹤0.01% 1940
2023
Q2
$182K Sell
6,051
-218
-3% -$7.63K ﹤0.01% 1915
2023
Q1
$227K Buy
6,269
+923
+17% +$35.5K ﹤0.01% 1802
2022
Q4
$191K Sell
5,346
-513
-9% -$17.8K ﹤0.01% 1890
2022
Q3
$198K Sell
5,859
-835
-12% -$27.2K ﹤0.01% 1858
2022
Q2
$194K Sell
6,694
-2,879
-30% -$82.5K ﹤0.01% 1902
2022
Q1
$309K Sell
9,573
-3,077
-24% -$94.3K ﹤0.01% 1748
2021
Q4
$369K Sell
12,650
-266
-2% -$8.07K ﹤0.01% 1685
2021
Q3
$344K Sell
12,916
-769
-6% -$20.6K ﹤0.01% 1701
2021
Q2
$421K Buy
13,685
+619
+5% +$19K ﹤0.01% 1638
2021
Q1
$342K Buy
13,066
+1,784
+16% +$49.9K ﹤0.01% 1691
2020
Q4
$284K Sell
11,282
-1,664
-13% -$35.8K ﹤0.01% 1719
2020
Q3
$269K Sell
12,946
-3,822
-23% -$86.7K ﹤0.01% 1635
2020
Q2
$399K Sell
16,768
-3,501
-17% -$77.4K ﹤0.01% 1419
2020
Q1
$365K Sell
20,269
-527
-3% -$11.1K ﹤0.01% 1378
2019
Q4
$493K Sell
20,796
-5,802
-22% -$141K ﹤0.01% 1383
2019
Q3
$732K Sell
26,598
-5,638
-17% -$167K ﹤0.01% 1188
2019
Q2
$1.07M Sell
32,236
-8,018
-20% -$275K ﹤0.01% 1039
2019
Q1
$1.41M Buy
40,254
+4,268
+12% +$159K ﹤0.01% 924
2018
Q4
$1.2M Buy
35,986
+7,267
+25% +$312K ﹤0.01% 929
2018
Q3
$1.45M Buy
28,719
+4,846
+20% +$239K ﹤0.01% 933
2018
Q2
$1.43M Sell
23,873
-917
-4% -$47.5K ﹤0.01% 937
2018
Q1
$1.14M Sell
24,790
-2,902
-10% -$121K ﹤0.01% 1025
2017
Q4
$1.1M Sell
27,692
-4,391
-14% -$174K ﹤0.01% 1049
2017
Q3
$1.28M Sell
32,083
-5,939
-16% -$257K ﹤0.01% 974
2017
Q2
$1.64M Sell
38,022
-2,968
-7% -$106K 0.01% 848
2017
Q1
$1.28M Sell
40,990
-9,108
-18% -$244K ﹤0.01% 958
2016
Q4
$1.26M Sell
50,098
-4,410
-8% -$98.5K ﹤0.01% 946
2016
Q3
$1.35M Sell
54,508
-5,296
-9% -$120K 0.01% 884
2016
Q2
$1.22M Buy
59,804
+1,205
+2% +$21.4K ﹤0.01% 906
2016
Q1
$893K Sell
58,599
-7,985
-12% -$104K ﹤0.01% 1037
2015
Q4
$894K Buy
66,584
+34,405
+107% +$532K ﹤0.01% 1019
2015
Q3
$451K Buy
32,179
+28,441
+761% +$529K ﹤0.01% 1340
2015
Q2
$63K Sell
3,738
-8,027
-68% -$114K ﹤0.01% 2410
2015
Q1
$142K Hold
11,765
﹤0.01% 1942
2014
Q4
$98K Buy
11,765
+715
+6% +$6.01K ﹤0.01% 2155
2014
Q3
$96K Hold
11,050
﹤0.01% 2124
2014
Q2
$121K Hold
11,050
﹤0.01% 2034
2014
Q1
$99K Hold
11,050
﹤0.01% 2119
2013
Q4
$83K Hold
11,050
﹤0.01% 2201
2013
Q3
$81K Buy
+11,050
New +$74.2K ﹤0.01% 2133

Other funds holding SUPN

US Bancorp's SUPN Position: Q2 2026 in Review

US Bancorp reduced its Supernus Pharmaceuticals (SUPN) stake by 89% in Q2 2026, selling an estimated $78.5K and leaving 205 shares worth $9.54K. The position accounts for ﹤0.01% of the portfolio, ranked #3458.

US Bancorp first reported a position in SUPN in Q3 2013 and has held it in 52 quarters since. The position peaked at $1.64M in Q2 2017. 332 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • US Bancorp held 205 shares of Supernus Pharmaceuticals worth $9.54K as of Q2 2026.
  • US Bancorp sold 1,635 Supernus Pharmaceuticals shares in Q2 2026, an estimated $78.5K.
  • Supernus Pharmaceuticals made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #3458 holding.
  • US Bancorp first reported a position in Supernus Pharmaceuticals in Q3 2013 and has held it in 52 quarters since.
  • US Bancorp's Supernus Pharmaceuticals position peaked at $1.64M in Q2 2017.
  • 332 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.